A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients

Oncology

Volumn 82, Issue 2, 2012, Pages 75-82

  Santini, Daniele ^a   Virzi, Vladimir ^a   Vasile, Enrico ^b   Vincenzi, Bruno ^a   Catalano, Vincenzo ^c   Graziano, Francesco ^c   Masi, Gianluca ^b   Bronte, Giuseppe ^d   Russo, Antonio ^d   Falcone, Alfredo ^b   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Division of Medical Oncology   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Biliary tract cancer; Capecitabine; Fixed dose rate; Gemcitabine

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CAPECITABINE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FATIGUE; FEMALE; FIXED DOSE RATE; GALLBLADDER CANCER; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEUTROPENIA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SMALL INTESTINE CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 84856767792     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000329079     Document Type: Article

References (41)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378.
2. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19: 4089-4091. (Pubitemid 32976699)
3. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186. (Pubitemid 32223865)
4. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902. (Pubitemid 46452283)
5. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. (Pubitemid 27251144)
6. Kindler HL: Front-line therapy of advanced pancreatic cancer. Semin Oncol 2005; 32:S33-S36. (Pubitemid 43080912)
7. Rudi J: Chemotherapy with gemcitabine in patients with gall-bladder carcinoma. Ann Oncol 2002; 13: 807. (Pubitemid 34567391)
8. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′ ,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567-572. (Pubitemid 20356209)
9. Ren Q, Kao V, Grem JL: Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998; 4: 2811-2818. (Pubitemid 28523510)
10. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281. (Pubitemid 28342121)
11. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297. (Pubitemid 30151522)
12. Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 2008; 13: 415-423. (Pubitemid 351679921)
13. Santini D, Virzi V, Vincenzi B, Rocci L, Leoni V, Tonini G: A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. Ann Oncol 2007; 18: 576-580. (Pubitemid 46359642)
14. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
15. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 2′ ,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 1990; 50: 6823-6826. (Pubitemid 20361074)
16. Therasse P: Measuring the clinical response. What does it mean? Eur J Cancer 2002; 38: 1817-1823. (Pubitemid 35256090)
17. National Cancer Institute CTC v2.0. www. eortc.be/Services/Doc/ctc/ CTCvs2.doc.
18. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600. (Pubitemid 26285639)
19. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
20. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M: A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403-1406. (Pubitemid 33100245)
21. Kuhn R, Hribaschek A, Eichelmann K, Rudolph S, Fahlke J, Ridwelski K: Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002;20:351-356. (Pubitemid 34823765)
22. Taieb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M: Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002; 13:1192-1196. (Pubitemid 34960126)
23. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhofer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309-315. (Pubitemid 351161262)
24. Reyes-Vidal JG, Yanez E, Rosas J, Palma M, Cerda B, Loredo E, Del Castillo C, Arriagada R, Quijada I: Gemcitabine (G) and cisplatin (C) in the treatment of patients (pts) with unresectable or metastatic gallbladder cancer: results of the phase II GOCCHI study 2000-13. ASCO Annual Meeting, 2003.
25. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer, II, Wolff RA, Charnsangavej C, Brown TD: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101:578-586. (Pubitemid 38970609)
26. Eng C, Ramanathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL: A Phase II trial of fixed dose rate gemcitabine in patients with advanced bilia-ry tree carcinoma. Am J Clin Oncol 2004;27:565-569. (Pubitemid 39603269)
27. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F, Scheithauer W: Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004;15:478-483. (Pubitemid 38444553)
28. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-2338. (Pubitemid 46218726)
29. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR: Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005;92:1650-1654. (Pubitemid 40756474)
30. Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B: A randomised phase II trial of weekly highdose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005;41:398-403. (Pubitemid 40187211)
31. Julka PK, Puri T, Rath GK: A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int 2006;5:110-114.
32. Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, Im SA, Kim TY, Bang YJ: Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol 2009;24:800-805.
33. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-3074. (Pubitemid 46638942)
34. Manzione L, Romano R, Germano D: Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology 2007;73:311-315. (Pubitemid 351862021)
35. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007;60:321-328. (Pubitemid 46944586)
36. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ: Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007;110:1307-1312. (Pubitemid 47435603)
37. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-867.
38. Im S, Kim Y, Kim H, Oh S, Choi I, Oh D, Kim J, Kim T, Kim S, Yoon Y, Bang Y: The role of thymidylate synthase as a pharmacogenomic predictor in a phase II trial of S-1/cisplatin in patients with metastatic or relapsed biliary tract cancer (BTC). Gastrointestinal Cancers Symposium, 2008.
39. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A: S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2008;62:849-855.
40. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS: Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008;53:564-570. (Pubitemid 351170025)
41. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J: Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-The UK ABC-01 Study. Br J Cancer 2009;101:621-627.